326 related articles for article (PubMed ID: 24868080)
1. A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer.
Okamoto K; Okamoto I; Takeda M; Kobayashi S; Takeda K; Nakamatsu K; Nishimura Y; Nakagawa K
Jpn J Clin Oncol; 2014 Aug; 44(8):743-8. PubMed ID: 24868080
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients.
Okamoto K; Okamoto I; Takezawa K; Tachibana I; Fukuoka M; Nishimura Y; Nakagawa K
Jpn J Clin Oncol; 2010 Jan; 40(1):54-9. PubMed ID: 19837690
[TBL] [Abstract][Full Text] [Related]
3. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
[TBL] [Abstract][Full Text] [Related]
5. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation
with Concurrent Twice-daily Radiotherapy for Patients
with Limited-stage Small Cell Lung Cancer].
You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
[TBL] [Abstract][Full Text] [Related]
6. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
7. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
Turrisi AT; Kim K; Blum R; Sause WT; Livingston RB; Komaki R; Wagner H; Aisner S; Johnson DH
N Engl J Med; 1999 Jan; 340(4):265-71. PubMed ID: 9920950
[TBL] [Abstract][Full Text] [Related]
8. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
[TBL] [Abstract][Full Text] [Related]
9. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer.
Xia B; Hong LZ; Cai XW; Zhu ZF; Liu Q; Zhao KL; Fan M; Mao JF; Yang HJ; Wu KL; Fu XL
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):517-23. PubMed ID: 25481679
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer.
Watkins JM; Wahlquist AE; Shirai K; Garrett-Mayer E; Aguero EG; Fortney JA; Sherman CA; Sharma AK
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1108-13. PubMed ID: 19084345
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study.
Le QT; McCoy J; Williamson S; Ryu J; Gaspar LE; Edelman MJ; Dakhil SR; Sides SD; Crowley JJ; Gandara DR;
Clin Cancer Res; 2004 Aug; 10(16):5418-24. PubMed ID: 15328179
[TBL] [Abstract][Full Text] [Related]
13. Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
Xenidis N; Kotsakis A; Kalykaki A; Christophyllakis Ch; Giassas S; Kentepozidis N; Polyzos A; Chelis L; Vardakis N; Vamvakas L; Georgoulias V; Kakolyris S
Lung Cancer; 2010 Jun; 68(3):450-4. PubMed ID: 19783319
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
15. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer.
Hirose T; Mizutani Y; Ohmori T; Ishida H; Hosaka T; Ando K; Shirai T; Okuda K; Ohnishi T; Horichi N; Kubota H; Adachi M
Cancer Chemother Pharmacol; 2006 Sep; 58(3):361-7. PubMed ID: 16331494
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
[TBL] [Abstract][Full Text] [Related]
17. [Pilot study of dose intensive weekly chemotherapy followed by cisplatin plus etoposide with concurrent thoracic irradiation for limited-disease small-cell lung cancer. West Japan Thoracic Oncology Group].
Isobe T; Fukuoka M; Negoro S; Sugiura T; Kawahara M; Kudoh S; Araki J; Nakagawa K; Yokozaki M; Yamakido M; Ariyoshi Y
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1091-6. PubMed ID: 10945001
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12.
Komaki R; Swann RS; Ettinger DS; Glisson BS; Sandler AB; Movsas B; Suh J; Byhardt RW
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):342-50. PubMed ID: 15890573
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12.
Glisson B; Scott C; Komaki R; Movsas B; Wagner H
J Clin Oncol; 2000 Aug; 18(16):2990-5. PubMed ID: 10944132
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer.
Segawa Y; Ueoka H; Kiura K; Tabata M; Takigawa N; Hiraki Y; Watanabe Y; Yonei T; Moritaka T; Hiyama J; Hiraki S; Tanimoto M; Harada M;
Lung Cancer; 2003 Jul; 41(1):13-20. PubMed ID: 12826307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]